https://assets.capyfin.com/instruments/678fdc13234e27009c5d5ba0.png avatar
West Pharma
🇺🇸 NYSE:WST
•
Dec 31, 2024

West Pharma Q4 2024 Earnings Report

Key Takeaways

West Pharmaceutical Services reported a 2.3% increase in revenue for Q4 2024, driven by strong demand for high-value self-injection devices. However, EPS declined slightly due to higher costs and currency headwinds.

Total Revenue
$749M
Previous year: $732M
+2.3%
EPS
$1.82
Previous year: $1.83
-0.5%
Organic Net Sales Growth
3.3%
Gross Margin
36.5%
Previous year: 38%
-3.9%
Operating Margin
21.3%
Previous year: 22%
-3.2%
Gross Profit
$274M
Previous year: $278M
-1.7%
Cash and Equivalents
$485M
Previous year: $854M
-43.2%
Free Cash Flow
$276M
Previous year: $130M
+112.0%

West Pharma Revenue

West Pharma EPS

West Pharma Revenue by Segment

Forward Guidance

West expects 2025 revenue to grow 2-3% organically, driven by self-injection devices, biologics, and GLP-1 therapies. However, currency exchange and cost pressures may weigh on earnings.

Positive Outlook

  • Continued growth in high-value self-injection devices.
  • Strong demand in biologics and generics markets.
  • Operational improvements driving efficiency.
  • Stable revenue guidance despite market volatility.
  • Focus on high-margin product expansion.

Challenges Ahead

  • Foreign exchange expected to be a $75M headwind.
  • EPS guidance reflects a potential decline.
  • Higher operating costs impacting profitability.
  • Softness in certain product categories.
  • Continued pricing pressures in key segments.

Revenue & Expenses

Visualization of income flow from segment revenue to net income